Trevena Inc (TRVN) Receives a New Rating from H.C. Wainwright


In a report released today, Douglas Tsao from H.C. Wainwright initiated coverage with a Buy rating on Trevena Inc (TRVN) and a price target of $3.50. The company’s shares closed yesterday at $1.19.

Tsao commented:

“Our $3.50 price target for Trevena is based on our sum-of-the-parts NPV valuation based on each of the company’s pipeline assets. Our DCF model utilizes a discount rate of 11.5% based on the company’s WACC (Beta of 1.5, equity risk premium of 6.7%). We adjust each indication for probability of success with 3 program has been successful, and we’re confident on the outcome of the cardiac safety study; TRV-250 at 15%; and TRV-045 at 7%. We don’t include TRV-734 in our valuation for the time being, although would look to add it to our valuation model as we gain additional insight. We apply terminal decline rates of 10% for each asset. We assume a 24% tax rate.”

According to TipRanks.com, Tsao is a 3-star analyst with an average return of 1.8% and a 51.6% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals Inc, Minerva Neurosciences, and Revance Therapeutics.

Currently, the analyst consensus on Trevena Inc is a Moderate Buy with an average price target of $3.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.58 and a one-year low of $0.38. Currently, Trevena Inc has an average volume of 1.5M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Trevena, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system, or CNS. The company product pipeline consists of Olinvo, TRV250, and TRV734.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts